Gistem Research S.L.

What Gistem Research S.L. does

Gistem Research S.L. is a Spanish biotechnology company founded in 2016 and headquartered in Gijón, Asturias, that develops therapeutic candidates derived from human Uterine Cervical Stem Cells (hUCESC). Its core technology platform centers on the production and application of the cell secretome and exosomes — the bioactive molecules and extracellular vesicles released by these stem cells — rather than the cells themselves. The company advances multiple preclinical programs targeting dry eye disease, inflammatory bowel disease, oral diseases, oncology, and, more recently, cerebral palsy.

Its intellectual property is anchored by patent family PCT/2014/053508, granted in more than 30 jurisdictions including the United States (granted 2025-02-04), Europe (granted 2019-06-17), China, Japan, Mexico, and Australia. Gistem is led scientifically by founders Dr. Francisco Vizoso Piñeiro and Dra. Noemí Eirí­o Díaz, with Dr. Luis Alberto Costa Pérez chairing its Board, and operates with a team of approximately six employees. It maintains a research network with the Jove Hospital Foundation, FICEMU, the University of Santiago de Compostela, the Ministry of Health of Tucumán (Argentina), and the Dale que valen Foundation.

Gistem is pre-clinical and pre-revenue. Its intended business model is to advance its programs through early clinical development and ultimately monetize the platform through out-licensing, co-development partnerships, or future royalty streams; two programs are targeted to enter clinical trials in 2026 and 2027, following positive guidance from the Spanish Medicines Agency on trial design. To date, the only disclosed funding is an IDEPA grant awarded in 2018.

Name

Gistem Research S.L.

Legal name

GISTEM RESEARCH, S.L.

Website

https://gistemresearch.com

Company type

Private

Founded year

2016

Operating status

Operating

Short description

Gistem Research S.L. is a Spanish biotechnology company developing secretome and exosome-based therapies derived from human Uterine Cervical Stem Cells (hUCESC) for ophthalmology, inflammatory bowel disease, oral conditions, oncology, and cerebral palsy applications.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Biotechnology

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industries

Exosome & Extracellular Vesicle (EV) Therapeutics (HLAMANAE), Stem Cell–Based Regenerative Therapies (HLAAAGAA)

Keywords

• Stem cell therapies
• Regenerative medicine
• Cell secretome research
• Extracellular vesicles
• Biotechnology research

Headquarters

HQ city

Gijón

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Stem Cell Derivative Products: Development and commercialization of secretome-based therapeutic products for various clinical applications including dry eye syndrome, inflammatory bowel disease, oral diseases, and oncology. Revenue expected from future product sales following clinical development.
2. Technology Licensing: Licensing of proprietary hUCESC technology, cell populations, and production methods to pharmaceutical and biotechnology partners.
3. Research Collaborations: Collaborative research arrangements with academic institutions and healthcare organizations for specific therapeutic applications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Gistem Research S.L. develops therapeutic products derived from stem cell derivatives, specifically the secretome and extracellular vesicles (exosomes) from human Uterine Cervical Stem Cells (hUCESC). The company produces these biological materials through reproducible, cost-effective methods and targets multiple clinical indications including dry eye syndrome, inflammatory bowel disease, oral diseases, and oncology. Two lead programs are expected to enter clinical trials in 2026 and 2027.

Product overview

Gistem Research S.L. operates as a pioneering biotechnology company focused on developing innovative therapies based on stem cell derivatives. The company's core technology platform centers on hUCESC (human Uterine Cervical Stem Cells) secretome and extracellular vesicles, which are produced in a reproducible and cost-effective manner. The product portfolio includes secretome-based therapeutic products for multiple clinical applications, specifically organized into therapeutic programs targeting Dry Eye Syndrome, Inflammatory Bowel Disease, Oral Diseases, and Oncology. The company's first two programs are expected to enter clinical phase in 2026 and 2027. The therapeutic approach focuses on using stem cell derivatives (secretome and extracellular vesicles) rather than live cells directly, which simplifies regulatory pathways as biological products rather than advanced therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• hUCESC Secretome-based Therapy Secretome-based therapeutic products derived from human Uterine Cervical Stem Cells (hUCESC), containing bioactive molecules offering immunoregulation, healing, and regeneration properties for pharmaceutical partners and healthcare institutions.
• hUCESC Extracellular Vesicles (Exosomes) Extracellular vesicles derived from human Uterine Cervical Stem Cells (hUCESC), used as therapeutic agents for clinical applications.
• Dry Eye Syndrome Therapeutic Program Clinical program targeting dry eye syndrome using secretome-based therapy derived from hUCESC, one of the company's first two lead programs.
• Inflammatory Bowel Disease Therapeutic Program Clinical program targeting inflammatory bowel disease using secretome-based therapy derived from hUCESC.
• Oral Diseases Therapeutic Program Clinical program targeting oral diseases and dental pulp regeneration using secretome-based therapy derived from hUCESC.
• Oncology Therapeutic Program Clinical program targeting oncology applications using secretome-based therapy derived from hUCESC, with research showing antitumor effects in breast cancer models.

Quantifiable outcome

• Improvement in 90% of uveitis cases with current treatment comparison
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and major.

• Dale que valen FoundationcoreStrategic or Co-development Partner · 4 March 2026Agreement to establish collaboration framework for research project 'Exploration of the therapeutic effect of intrasanal application of secretome derived from mesenchymal stem cells of the human uterine cervix in cerebral palsy.' Project encompasses complete cycle up to obtaining therapeutic solutions and treatment protocols.
• Ministry of Health of TucumáncoreStrategic or Co-development Partner · 22 May 2025Framework cooperation agreement between the Ministry of Health of Tucumán (Argentina), GiStem Research S.L., and the Economic Federation for stem cell research. The agreement focuses on secretome-based therapies and includes plans for specific protocols with ethics committee approval for work with selected patients.
• Economic Federation of Tucumán (FET)coreStrategic or Co-development Partner · 22 May 2025Partnered with Ministry of Health of Tucumán and GiStem Research for stem cell research cooperation. FET facilitated Dr. Luis Costa Pérez's involvement and is financing the project.
• Jove Hospital FoundationcoreStrategic or Co-development PartnerLong-standing research collaboration with the Jove Hospital Foundation in Gijón, where the research unit is located and where initial stem cell research was conducted.
• FICEMU (Foundation for Uterine Stem Cell Research)coreStrategic or Co-development PartnerFoundation supporting research with uterine stem cells. Dr. Francisco Vizoso serves as Director of the Scientific Committee. The foundation has financed multiple research projects.
• University of Santiago de CompostelamajorStrategic or Co-development PartnerAcademic research partner collaborating on various studies including stem cell applications in cancer, ophthalmology, and inflammatory conditions. Located in Galicia, Spain.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Capricor Therapeutics: US clinical-stage biotechnology company developing exosome and cell-based therapeutics, notably its lead exosome program CAP-1002 and Deramiocel for Duchenne muscular dystrophy. Directly comparable to Gistem as a stem cell-derived exosome platform targeting inflammatory and regenerative indications.
• Direct Biologics: US-based biotech developing extracellular vesicle (EV) and exosome-based therapies derived from bone marrow mesenchymal stem cells for inflammatory and regenerative indications including wound healing and orthopedic applications. Closely comparable to Gistem's hUCESC-derived exosome platform in technology and target markets.
• Kimera Labs: US biotech focused on mesenchymal stem cell-derived exosome products for regenerative and wellness applications. Direct peer in the MSC-exosome therapeutics space with similar therapeutic claims around immunoregulation and tissue regeneration.
• ExoCoBio: South Korea-based exosome therapeutics developer with MSC-derived exosome products for skin regeneration, atopic dermatitis, and inflammatory conditions. Direct competitor in the cell-derived exosome therapeutics category targeting similar indications.
• Cynata Therapeutics: Australia-based clinical-stage biotech developing iPSC-derived mesenchymal stem cell therapies (CYP-001, CYP-004) for inflammatory conditions including osteoarthritis and GVHD. Directly comparable MSC-derived therapeutic platform targeting similar regenerative and immunoregulatory indications.
• Pluri Inc. Israel-based clinical-stage biotech developing placenta-derived MSC therapies (PLX cells) for inflammatory and regenerative indications. Comparable as a non-traditional MSC source (placenta vs. uterine cervical) targeting overlapping therapeutic areas with cell-based and cell-derived approaches.
• Regeneus: Australia-based clinical-stage biotech developing adipose-derived stem cell and secretome-based therapies (Progenza, Sygenus) for osteoarthritis and inflammatory pain. Directly comparable as a stem cell-derived secretome platform with similar mechanism and indications.
• Celltex Therapeutics: US-based biotech specializing in autologous and allogeneic mesenchymal stem cell banking and therapy development for degenerative and inflammatory conditions. Peer in the mesenchymal stem cell therapy space with similar regenerative medicine focus.

Broad incumbents

• Mesoblast: Australia-listed clinical-stage biotech developing mesenchymal stem cell-derived therapies (Remestemcel-L, Ryoncil) for inflammatory and immune-mediated diseases including GVHD and heart failure. Larger, more advanced MSC-therapy incumbent with overlapping technology platform and indication strategy.
• Athersys: US-based clinical-stage biotech developing MultiStem, a proprietary adult stem cell platform for inflammatory, neurological, and cardiovascular indications. Broader incumbent in regenerative medicine with overlapping platform philosophy and target disease areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/gistemresearchs.l.

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gistem Research S.L.